Dipivefrin, an ophthalmic drug used to reduce intraocular pressure in patients with glaucoma, was developed in the 1970s and approved for medical use in the early 1980s. Its history is marked by its effectiveness in lowering intraocular pressure while minimizing systemic side effects compared with epinephrine. Dipivefrin, a prodrug of epinephrine, is converted in the eye to its active form, providing targeted action for glaucoma management. Its development included extensive clinical testing to ensure safety and efficacy, leading to widespread adoption in combination therapy regimens for patients with open-angle glaucoma or ocular hypertension.
BRAND NAMES
Propine – the most widely recognized brand, typically used as a 0.1% ophthalmic solution for lowering intraocular pressure in glaucoma patients.
Glaucon – available in some regions as an alternative formulation of dipivefrin eye drops.
MECHANISM OF ACTION
The mechanism of action of Dipivefrin involves its function as a prodrug of epinephrine. After being administered as an ophthalmic solution, dipivefrin is converted enzymatically to epinephrine in the cornea, which then activates α- and β-adrenergic receptors in the eye. Activation of these receptors increases aqueous humor outflow through the trabecular meshwork and reduces aqueous humor production by the ciliary body, resulting in a lowering of intraocular pressure.
PHARMACOKINETICS
Absorption
The absorption of Dipivefrin occurs primarily through the cornea and conjunctiva after topical ocular administration. Once applied as an eye drop, dipivefrin is rapidly absorbed into the anterior chamber of the eye, where it is enzymatically converted to its active form, epinephrine.
Distribution
The volume of distribution (Vd) of Dipivefrin is relatively limited, reflecting its primarily local action within the eye. After topical ocular administration, most of the drug remains in the anterior chamber and ocular tissues, with only minimal systemic absorption.
Metabolism
The metabolism of Dipivefrin occurs primarily in the eye and liver. After topical administration, dipivefrin is enzymatically converted in the cornea to its active form, epinephrine, which then exerts its intraocular pressure–lowering effect.
Elimination
The elimination of Dipivefrin occurs mainly through renal excretion after systemic absorption. Once dipivefrin is converted to epinephrine in the eye, the active drug that enters the bloodstream is metabolized in the liver to inactive metabolites, including metanephrine and vanillylmandelic acid (VMA), which are then excreted in the urine.
PHARMACODYNAMICS
The pharmacodynamics of Dipivefrin are primarily based on its role as a prodrug of epinephrine. After topical ocular administration, dipivefrin is converted to epinephrine in the cornea, which then stimulates α- and β-adrenergic receptors in the eye. This leads to increased aqueous humor outflow through the trabecular meshwork and reduced aqueous humor production by the ciliary body, resulting in a decrease in intraocular pressure.
ADMINISTRATION
The administration of Dipivefrin is topical, applied as eye drops directly to the conjunctival sac. The typical regimen involves one drop in the affected eye(s) two to four times daily, depending on the patient’s intraocular pressure and response to therapy.
DOSAGE AND STRENGTH
The dosage and strength of Dipivefrin are formulated for topical ocular administration as a 0.1% ophthalmic solution, with each milliliter containing 1 mg of dipivefrin. The usual regimen for adults involves instilling one drop in the affected eye(s) two to four times daily, depending on the patient’s intraocular pressure and therapeutic response.
DRUG INTERACTIONS
The drug interactions of Dipivefrin are primarily related to its adrenergic activity. Concomitant use with other sympathomimetic agents may potentiate systemic adrenergic effects such as increased heart rate, elevated blood pressure, or arrhythmias. Combining dipivefrin with monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants can also enhance these cardiovascular effects.
FOOD INTERACTIONS
The food interactions of Dipivefrin are minimal, as it is administered topically as eye drops and absorption through the gastrointestinal tract is negligible. Therefore, diet does not affect its efficacy or pharmacokinetics.
CONTRAINDICATIONS
The contraindications of Dipivefrin include known hypersensitivity to dipivefrin, epinephrine, or any component of the formulation. It should not be used in patients with narrow-angle glaucoma, as adrenergic stimulation may worsen intraocular pressure in these cases.
SIDE EFFECTS
Eye irritation or stinging upon instillation
Blurred vision temporarily after administration
Tearing or watery eyes
Headache
OVER DOSAGE
Overdosage of Dipivefrin can result from excessive topical application or accidental ingestion and may lead to systemic adrenergic effects. Symptoms of overdose include rapid heart rate (tachycardia), elevated blood pressure, palpitations, headache, nervousness, dizziness, nausea, and vomiting. In severe cases, cardiac arrhythmias, chest pain, or hypertensive crisis may occur.
TOXICITY
Toxicity of Dipivefrin arises primarily from excessive adrenergic stimulation, either due to overdose or inappropriate frequent use. Clinical manifestations include tachycardia, hypertension, palpitations, headache, dizziness, nervousness, and nausea. In severe cases, systemic toxicity can lead to cardiac arrhythmias, chest pain, or hypertensive crisis, particularly in patients with preexisting cardiovascular disease.
